Robert Giannini, Ph.D. Vice President, Innovation
Robert Giannini brings more than 30 years of pharmaceutical industry experience as vice president of innovation at Recro. His knowledge includes developing a wide range of dosage forms such as controlled/extended release solids, oral liquids, and injectables. He has been responsible for all aspects of dosage form development and manufacture: pre-formulation, formulation development, analytical methodology, stability, process validation, regulatory compliance/submissions, and day-to-day production for currently marketed products. Robert joined IriSys, now a Recro company, in 2004 and has been the primary author and principal investigator on most of the company’s proposals that resulted in NIH development and manufacturing contracts.
From 1981 to 1985, Bob served as a senior scientist — solid dosage forms, and then as a unit supervisor — novel drug delivery systems at Wyeth Laboratories. In 1985 he joined Key/Schering Plough as section head — solid dosage form development. This was followed by a position as vice president — pharmaceutical research and development at a small venture capital-funded firm called Himedics. In 1991, he joined Watson Laboratories as director of product development, where he was responsible for the development of generic products from formulation to ANDA submission.
Robert was awarded a Ph.D. in Industrial Pharmacy from the University of Maryland at Baltimore for research in the area of solid dosage form design.